Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
2.450
+0.220 (9.87%)
At close: Aug 13, 2025, 4:00 PM
2.410
-0.040 (-1.63%)
Pre-market: Aug 14, 2025, 9:21 AM EDT
Iovance Biotherapeutics Employees
Iovance Biotherapeutics had 838 employees as of December 31, 2024. The number of employees increased by 281 or 50.45% compared to the previous year.
Employees
838
Change (1Y)
281
Growth (1Y)
50.45%
Revenue / Employee
$288,216
Profits / Employee
-$465,300
Market Cap
886.54M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
IOVA News
- 6 days ago - Iovance Biotherapeutics, Inc. (IOVA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025 - GlobeNewsWire
- 21 days ago - Here's why Iova stock surged 32% today and why the rally might not be over - Invezz
- 26 days ago - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 26 days ago - Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug - Seeking Alpha
- 4 weeks ago - Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer - GlobeNewsWire
- 4 weeks ago - IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV - PRNewsWire
- 4 weeks ago - Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma - GlobeNewsWire